MoonLake Immunotherapeutics

NASDAQ:MLTX

Biotechnology

Healthcare
$10.79 +0.69%

+$0.13 today

Market cap
$918.30M
Beta
1.04
P/E (TTM)
-5.4
EPS (TTM)
-$3.61
52W Low $5.95High $62.75

Volume 1.32M

Average 0.99M

MLTX Sales of Investments

Cash received from selling or redeeming investments.

MoonLake ImmunotherapeuticsNASDAQ: MLTX

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments dips below year-ago levels

Q1 FY2026 sales of investments of $59.17M fell 59.1% year over year, behind the +65.8% change in trailing-twelve-month sales of investments. Sequentially, it rose 102.2% from the prior quarter. Over 3 fiscal years it compounded at +261.7% a year.

Context

  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -59.1% toward the trailing-twelve-month pace of +65.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$59.17M+102.2% QoQ
Last fiscal yearDec 2025
$468.4M+222.6% YoY
LTMMar 2026
$382.74M+65.8% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.1%——
1 year+222.6%——
3-year CAGR+261.7%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
468.4M USD
Year-over-year change
+222.6%

Sales of Investments vs competitors

How MLTX compares with its peers on the latest reported figures

  • MLTX's LTM Mar 2026 sales of investments of $382.74M is the 4th largest of the 11 companies compared; the peer median is $236.43M.
  • Its year-over-year change of +65.8% is the 5th highest of 10, against a peer median of +47.6%.
  • Over three fiscal years its annual growth of +261.7% compares with a peer median of +5.0%.
MLTX Competitors Peer median
Sales of Investments for MLTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$614.95M +3.0%+30.4%87.6%
ALMSAlumis Inc. Common StockLTM Jun 2026$555.15M +110.1%+46.4%7504.0%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$405.29M +102.6%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$382.74M +65.8%+261.7%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$362.7M +47.6%+438.5%19049.4%
ANABAnaptysBio, Inc.LTM Mar 2026$322.1M -33.7%+1.3%138.6%
ATTOAttovia Therapeutics, Inc.FY2025$150.75M +1784.4%—11166.7%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$79.8M -19.5%-20.6%953.7%
CNTBConnect Biopharma Holdings LimitedFY2025$39.95M +216.4%+5.0%62417.2%
ZURAZura Bio LimitedLTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026$0 -100.0%-48.6%—
Peer median (excluding MLTX) $236.43M+47.6%+5.0%7504.0%

Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(53.64M)(49.97M)(44.08M)(121.24M)(229.1M)
Depreciation & Amortization4.97K12.36K13.16K1.38M2.62M
Deferred Income Tax00000
Stock-Based Compensation10.86M9.65M7.11M7.28M12.9M
Change in Working Capital4.48M(1.43M)(6.22M)(3.78M)19.88M
Accounts Receivables(148.77K)(68.36K)(840K)(1.79M)(2.03M)
Inventory00000
Accounts Payables1.57M(1.31M)000
Other Working Capital3.06M(44.8K)(6.22M)(2M)21.9M
Other Non-Cash Items13.98M(4.51M)399.51K(225.71K)(2.3M)
Operating Cash Flow(35.18M)(55.89M)(42.78M)(116.59M)(196.01M)
Capital Expenditures(50.71K)(16.01K)(284.63K)(519.52K)(35K)
Acquisitions (Net)00000
Purchases of Investments0(42.23M)(175.73M)(350.28M)(265.37M)
Sales of Investments09.9M150.83M145.2M468.4M
Other Investing Activities00000
Investing Cash Flow(50.71K)(32.34M)(25.18M)(205.6M)202.99M
Debt Repayment15M(15M)0073.02M
Common Stock Issued28.27M3.79K482.45M52.54M72.98M
Common Stock Repurchased(6.2K)00(50)0
Dividends Paid00000
Other Financing Activities0134.69M(2.75M)(1.23M)0
Financing Cash Flow43.26M119.69M479.7M51.31M146M
Effect of Forex Changes(1.33M)8.54K(75.31K)127.97K1.11M
Net Change in Cash6.7M31.47M411.66M(270.74M)154.09M
Free Cash Flow(35.23M)(55.91M)(43.06M)(117.11M)(196.04M)

MoonLake Immunotherapeutics

NASDAQ:MLTX

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.